Report Overview

The value of biological drugs indicated for autoimmune diseases, which affect up to 5% of the total world population, was roughly $11 billion in 2005. Remicade, Enbrel, Humira and Avonex currently lead the autoimmune field. These drugs are transforming the treatment of autoimmune diseases. In addition, novel therapies for psoriasis, asthma, and lupus will in the near future add tremendous revenue to an already rapidly growing field.

Medical, pharmaceutical and biotechnological advances are increasingly supporting the use of biological drugs in the treatment of autoimmune and inflammatory diseases. Indeed, biologics are having a major impact on the treatment of those diseases for which there has been significant unmet need for decades. As the new drugs are capable of targeting disease-causing proteins in a more specific fashion, while also carrying lower risks of adverse side effects, they have considerable advantages over traditional treatments. Given the above advantages, coupled with more commercial interest, better understanding of disease causes and higher levels of patient familiarity with the new medicines, biologics will continue to undermine the market share of traditional drugs.

This report assesses the current and future position of biologics in the fields of multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, psoriasis and asthma.

Key Features of This Report: